Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 4/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | HASPIN | Q8TF76 | 4/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.37 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 3/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276244 | 0.91 | MAPT (0.47) | CLK1DYRK1ACSNK1DCSNK1EMAPT | |
| SCHEMBL19049156 | 0.78 | PDPK1 (0.59) | CLK1DYRK1ACSNK1DCSNK1EMAPT | |
| SCHEMBL277601 | 0.75 | PDPK1 (0.60) | MAPTCYP2A6KDM4E | |
| SCHEMBL276964 | 0.74 | CLK1 (0.46) | CLK1DYRK1ACSNK1DCSNK1EMAPT | |
| SCHEMBL18459078 | 0.74 | CLK1 (0.46) | CLK1DYRK1ACSNK1DCSNK1EMAPT | |
| SCHEMBL23976335 | 0.74 | CLK1 (0.46) | CLK1DYRK1ACSNK1DCSNK1EMAPT | |
| SCHEMBL19445107 | 0.74 | CLK1 (0.46) | CLK1DYRK1ACSNK1DCSNK1EMAPT | |
| SCHEMBL2013355 | 0.74 | CLK1 (0.46) | CLK1DYRK1ACSNK1DCSNK1EMAPT | |
| SCHEMBL7980560 | 0.74 | CYP1A2 (0.59) | CLK1DYRK1ACSNK1DCSNK1EMAPT | |
| SCHEMBL30107523 | 0.74 | CLK1 (0.46) | CLK1DYRK1ACSNK1DCSNK1EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115341-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| EP-1636192-B9 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2014-02-20 | — | — | US | disclosed |
| EP-1636192-B1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-8552031-B2 | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8318796-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8093251-B2 | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-2025671-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| US-20090023939-A1 | ALPHA-SUBSTITUTED VINYLTIN COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1819692-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006062240-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | CLK1 3683/4885DYRK1A 2850/4885CSNK1D 1236/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | CLK1 3644/4885DYRK1A 2888/4885CSNK1D 1256/4885 |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | CLK1 3226/4885DYRK1A 2324/4885CSNK1D 2661/4885 |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | CLK1 3692/4885DYRK1A 2916/4885CSNK1D 1270/4885 |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | CLK1 3692/4885DYRK1A 2916/4885CSNK1D 1270/4885 |
| US-20090023939-A1 | ALPHA-SUBSTITUTED VINYLTIN COMPOUND | TST, CCNT1, TMT1A | CLK1 3907/4885DYRK1A 4498/4885CSNK1D 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.